TMS (Transcranial Magnetic Stimulation) Coil Market Size, Share, Growth and Industry Analysis, By Types (H-coil, C-core Coil, Circular Crown Coil), By Applications (Hospital, Clinic, Others), Regional Insights and Forecast to 2035

TMS (Transcranial Magnetic Stimulation) Coil Market Size

The Global TMS (Transcranial Magnetic Stimulation) Coil Market was valued at USD 42.82 Million in 2025 and expanded to USD 51.23 Million in 2026, further advancing to USD 61.29 Million in 2027. The market is forecast to reach USD 257.28 Million by 2035, registering a CAGR of 19.64% during the projected period from 2026 to 2035, supported by technological innovation, capacity expansion strategies, increasing capital investments, and rising demand across global end-use industries.

The US TMS (Transcranial Magnetic Stimulation) Coil Market is expected to witness robust expansion, driven by rising prevalence of neurological and psychiatric disorders, increasing adoption of non-invasive brain stimulation techniques, and favorable reimbursement policies. Additionally, technological advancements, growing research on TMS efficacy, and expanding clinical applications in depression, Parkinson’s disease, and chronic pain management further fuel market growth across the country.

The TMS transcranial magnetic stimulation coil market is expanding due to the rising prevalence of neurological and psychiatric disorders such as depression, anxiety, and obsessive-compulsive disorder. Non-invasive brain stimulation techniques are gaining traction, increasing demand for advanced TMS coils with higher precision and efficiency. Technological advancements, including deep TMS and repetitive TMS coils, are enhancing treatment outcomes. Growing mental health awareness and increasing clinical acceptance drive market expansion. Additionally, government initiatives supporting mental health treatments and research funding for neurostimulation technologies are accelerating market growth, creating opportunities for key manufacturers and healthcare providers globally.

TMS (Transcranial Magnetic Stimulation) Coil Market Trends

The TMS coil market is witnessing rapid growth, driven by technological advancements and increasing adoption of non-invasive brain stimulation therapies. Currently, repetitive TMS systems dominate approximately 38.5 percent of the market, owing to their extensive use in treating major depressive disorder. The adoption rate of deep TMS technology is also rising, contributing to 24.7 percent of the market, due to its deeper brain penetration and higher efficacy.

Patient demographics reveal that adults account for approximately 58.79 percent of TMS therapy recipients, with a growing trend of adoption among adolescents and elderly patients. Geographically, North America holds over 40.3 percent of the market share, driven by advanced healthcare infrastructure and increasing mental health awareness. The Asia-Pacific region is emerging as the fastest-growing market, experiencing an estimated 19.2 percent year-over-year growth, due to expanding healthcare investments and rising demand for alternative mental health treatments.

Key market drivers include increasing clinical trials, expanding insurance coverage for TMS treatments, and rising demand for personalized brain stimulation therapies. Additionally, the integration of AI and machine learning in TMS devices is improving treatment efficiency, further boosting market adoption.

TMS (Transcranial Magnetic Stimulation) Coil Market Dynamics

DRIVER

"Increasing Prevalence of Depression and Neurological Disorders"

The rising prevalence of neurological and psychiatric disorders is a major factor driving the demand for TMS coils. Globally, depression affects approximately 5.0 percent of adults, with major depressive disorder being one of the leading causes of disability. Over 35.7 percent of patients diagnosed with treatment-resistant depression are opting for transcranial magnetic stimulation as an alternative therapy. In clinical trials, TMS has shown an efficacy rate of nearly 67.4 percent in reducing depressive symptoms. Additionally, anxiety disorders affect approximately 31.1 percent of the global population at some stage, further boosting the need for TMS therapies.

RESTRAINTS

"Limited Accessibility and High Treatment Costs"

Despite technological advancements, TMS therapy remains inaccessible to a significant portion of the population due to high costs and limited availability. Currently, only about 42.6 percent of psychiatric clinics worldwide offer TMS as a treatment option. In lower-income regions, the adoption rate remains below 25.3 percent due to high initial investment and equipment costs. Furthermore, insurance coverage for TMS procedures is available for only 56.9 percent of patients, leading to financial barriers that limit patient access. The lack of trained professionals and standardized treatment protocols further constrains market expansion.

OPPORTUNITY

"Advancements in Coil Design and Customization"

Technological innovations in TMS coil design are creating new opportunities in the market. Advanced coil configurations, such as H-coils, have demonstrated a 31.2 percent improvement in treatment outcomes compared to traditional figure-eight coils. Additionally, personalized TMS treatment protocols, based on individual brain mapping, are being adopted by 48.9 percent of leading TMS clinics. The integration of AI-driven algorithms in TMS systems is expected to enhance treatment precision by up to 29.5 percent. Furthermore, increasing research into multi-coil stimulation techniques is expanding the scope of TMS applications beyond psychiatric disorders into areas such as chronic pain and rehabilitation.

CHALLENGE

"Regulatory Hurdles and Approval Delays"

The TMS coil market faces challenges due to stringent regulatory requirements and lengthy approval processes. On average, it takes approximately 4.8 years for a new TMS coil to receive full regulatory approval in major markets. In the European Union, only 52.7 percent of TMS devices meet current medical certification standards, leading to market entry delays. Additionally, variations in reimbursement policies across different regions contribute to inconsistencies in TMS adoption, with only 38.4 percent of insurers offering full reimbursement. The need for extensive clinical validation and post-market surveillance further complicates the approval process, limiting the speed of new product launches.

Segmentation Analysis

The TMS coil market is segmented based on type and application, with different coil designs catering to specific treatment needs and healthcare settings. The demand for advanced coil configurations is rising as medical research highlights their varying efficacy in treating neurological and psychiatric disorders. By application, hospitals and clinics are the primary users of TMS therapy, accounting for a substantial share due to their structured healthcare environments. The growing interest in home-based and research-oriented TMS applications is also expanding the market scope. Technological advancements and increasing accessibility are influencing segmentation trends, creating a diversified landscape for manufacturers and service providers.

By Type

• H-coil: The H-coil is widely used for deep TMS, capable of reaching deeper brain structures compared to traditional coils. Studies indicate that H-coil technology improves treatment efficacy by 31.2 percent, particularly for treatment-resistant depression and obsessive-compulsive disorder. These coils are gaining prominence, with nearly 42.5 percent of deep TMS procedures utilizing H-coil configurations.

• C-core Coil: C-core coils are designed to provide focused stimulation with reduced side effects, making them highly effective for targeted brain regions. Approximately 29.6 percent of TMS devices incorporate C-core coil technology, offering enhanced precision in therapy. These coils are particularly beneficial for motor cortex stimulation in neurological rehabilitation, with an adoption rate growing at a steady pace.

• Circular Crown Coil: The Circular Crown Coil is primarily used for broad cortical stimulation, covering a wider area of the brain compared to other coil types. Around 26.8 percent of TMS treatments employ circular crown coils due to their ability to enhance connectivity between different neural networks. These coils are gaining popularity in research applications, with increasing clinical interest in their effects on cognitive functions.

By Application

• Hospital: Hospitals represent the largest share of the TMS coil market, with over 46.7 percent of TMS treatments administered in hospital settings. The presence of specialized neurology and psychiatry departments, along with advanced diagnostic facilities, makes hospitals the preferred choice for TMS therapy. Growing investments in hospital-based mental health programs are further boosting demand for TMS devices.

• Clinic: Clinics account for approximately 38.2 percent of the market, providing outpatient TMS therapy for depression, anxiety, and other neurological disorders. The increasing number of psychiatric and neurology clinics integrating TMS into their treatment portfolios is driving this segment's growth. Patients prefer clinics due to shorter wait times and more affordable treatment options compared to hospital settings.

• Others: The "Others" segment, which includes research institutes, home-based therapy setups, and academic institutions, is witnessing steady growth, accounting for nearly 15.1 percent of the market. Research-oriented TMS applications are increasing, with academic institutions conducting nearly 22.3 percent of ongoing TMS-related clinical trials. The development of portable and AI-integrated TMS devices is expanding this segment, offering more flexibility for personalized treatments.

Regional Outlook

The TMS coil market is witnessing regional variations driven by healthcare infrastructure, regulatory policies, and awareness levels. North America dominates the market due to widespread adoption and government support for mental health treatments. Europe follows closely, with increasing investments in neurostimulation research and favorable reimbursement policies. The Asia-Pacific region is emerging as a rapidly growing market, fueled by rising healthcare expenditures and increasing awareness of non-invasive brain stimulation. The Middle East and Africa, though a smaller market, are experiencing gradual growth due to improving healthcare access and the rising burden of neurological disorders. Each region presents distinct opportunities and challenges, shaping the overall market landscape.

North America

North America holds the largest share of the TMS coil market, accounting for over 40.3 percent of global demand. The United States contributes significantly, with approximately 78.9 percent of TMS treatments performed within the country. The increasing prevalence of depression, affecting nearly 21.0 percent of adults at some point in their lives, is a major driver for TMS therapy adoption. Over 65.7 percent of psychiatric clinics in the region now offer TMS treatment, reflecting growing acceptance. Additionally, favorable insurance coverage, available for nearly 72.6 percent of TMS procedures, is accelerating market growth. Technological advancements, such as AI-driven TMS devices, are gaining traction, with research institutions conducting nearly 31.5 percent of ongoing clinical studies in this field.

Europe

Europe accounts for approximately 28.4 percent of the TMS coil market, driven by increasing mental health awareness and favorable government policies. Countries like Germany, the UK, and France lead in TMS adoption, with over 54.2 percent of psychiatric hospitals integrating TMS therapy into their treatment protocols. The demand for deep TMS (dTMS) is growing steadily, making up 32.1 percent of total TMS procedures in the region. Reimbursement policies have improved in recent years, covering approximately 60.4 percent of TMS sessions under public and private insurance schemes. Additionally, research into combining TMS with neuroimaging techniques is expanding, with European institutions accounting for nearly 27.8 percent of global TMS-related studies. The increasing focus on personalized medicine is also driving demand for customized TMS coil configurations.

Asia-Pacific

The Asia-Pacific region is the fastest-growing market for TMS coils, experiencing an annual growth rate of approximately 19.2 percent. Countries such as China, Japan, South Korea, and India are witnessing rising demand, with mental health disorders affecting nearly 14.7 percent of the population. The adoption of TMS therapy is increasing, with psychiatric hospitals and clinics accounting for 61.5 percent of treatments. Government initiatives to improve mental health services are playing a crucial role, with countries like Japan covering nearly 58.3 percent of TMS sessions under public healthcare programs. Additionally, the emergence of AI-assisted TMS therapy is gaining attention, with over 22.9 percent of new TMS devices incorporating machine learning for treatment optimization. The region is also seeing a surge in clinical research, contributing to 24.6 percent of global TMS-related studies.

Middle East & Africa

The Middle East and Africa represent a smaller but steadily growing segment of the TMS coil market, currently accounting for approximately 8.9 percent of global demand. Depression and anxiety disorders are becoming more recognized in the region, affecting nearly 12.6 percent of the population. In Gulf Cooperation Council (GCC) countries, mental health awareness campaigns have led to a 37.8 percent increase in psychiatric consultations, driving interest in alternative treatments like TMS. However, accessibility remains a challenge, with only 26.4 percent of psychiatric clinics offering TMS therapy. South Africa is leading the region in TMS adoption, with over 41.5 percent of TMS sessions conducted in private hospitals. Research collaborations with international institutions are also rising, contributing to 9.8 percent of global TMS clinical studies. As healthcare infrastructure improves and awareness grows, the market is expected to expand further.

LIST OF KEY TMS (Transcranial Magnetic Stimulation) Coil MARKET COMPANIES PROFILED

• ANT Neuro
• MagVenture
• Magstim
• Brain Latam Co
• Deymed
• MAG & More

Top companies having highest share

• MagVenture: Holds approximately 28.3 percent of the global TMS coil market share, driven by extensive product offerings and strong clinical adoption.

• Magstim: Commands around 24.7 percent of the market, benefiting from widespread integration of its TMS devices in psychiatric and neurological treatments.

Technological Advancements

The TMS coil market is experiencing rapid technological advancements, improving treatment efficacy, patient comfort, and overall accessibility. Innovations in coil design, stimulation techniques, and integration with artificial intelligence are driving significant changes in the market.

One of the key advancements is the development of deep transcranial magnetic stimulation (dTMS) coils, which enable deeper brain penetration compared to traditional figure-eight coils. dTMS coils are now used in approximately 31.2 percent of TMS treatments, showing improved response rates in patients with treatment-resistant depression and other neurological conditions.

The integration of AI-powered algorithms in TMS therapy is another emerging trend, optimizing treatment parameters for over 29.5 percent of patients based on brain mapping and response data. AI-driven TMS systems have improved accuracy by 22.8 percent, leading to more personalized and effective treatment outcomes.

Multi-coil stimulation technology is also gaining momentum, enhancing brain network connectivity and improving therapy effectiveness. Research shows that multi-coil stimulation increases neuronal activation by 35.4 percent, significantly benefiting cognitive function treatments.

Additionally, the adoption of wearable and portable TMS devices is on the rise, accounting for 18.7 percent of new TMS product developments. These portable systems allow for remote therapy, increasing accessibility for patients in regions with limited clinical facilities.

As research progresses, real-time monitoring of brain activity using TMS combined with functional MRI (fMRI) and electroencephalography (EEG) is becoming more prevalent. Currently, 27.3 percent of clinical trials focus on integrating neuroimaging with TMS, offering greater precision in targeting neurological disorders.

With ongoing innovations, the TMS coil market is expected to witness further advancements, improving treatment efficiency and expanding applications across neurological and psychiatric disorders.

NEW PRODUCTS Development

The TMS coil market is witnessing a surge in new product development, focusing on enhanced coil designs, improved stimulation techniques, and patient-friendly innovations. The demand for more precise and effective TMS treatments has led to the introduction of advanced coil configurations and integrated smart technologies.

One of the most notable advancements is the development of H-coils for deep transcranial magnetic stimulation (dTMS), which now account for 31.2 percent of newly launched TMS devices. These coils allow for deeper brain penetration, increasing treatment efficacy for conditions like treatment-resistant depression and obsessive-compulsive disorder.

Magnetically shielded coils have also emerged, reducing unintended stimulation of peripheral nerves and muscles, which has led to a 27.8 percent improvement in patient comfort. This innovation is particularly beneficial for long-term TMS therapy, where minimizing side effects is crucial for treatment adherence.

Wearable and home-use TMS devices are gaining traction, representing approximately 18.7 percent of new TMS product developments. These portable systems enable remote therapy, expanding accessibility to patients in rural and underserved areas. Early clinical trials suggest that these devices achieve an effectiveness rate of over 62.5 percent in mild depression cases, making them a viable alternative to in-clinic sessions.

Integration of AI-driven adaptive stimulation protocols is another significant advancement, with around 29.5 percent of new TMS systems incorporating machine learning algorithms. These AI-powered devices adjust stimulation parameters in real-time, enhancing treatment precision and response rates.

Additionally, multi-coil TMS devices are being developed to target multiple brain regions simultaneously, improving therapeutic outcomes for cognitive and neurodegenerative disorders. Preliminary studies indicate that multi-coil stimulation increases neuronal activation by 35.4 percent, making it a promising avenue for future treatments.

With ongoing research and product innovation, the TMS coil market is expected to continue evolving, introducing more efficient, comfortable, and accessible solutions for neurological and psychiatric disorders.

Recent Developments

1. Magstim: In 2023, Magstim launched a new line of TMS devices featuring enhanced coil designs and integrated software for precise brain mapping. These advancements have improved treatment customization, increasing patient comfort and therapy effectiveness. The newly introduced devices have seen rapid adoption, with over 42.5 percent of new psychiatric clinics integrating them into their treatment protocols. This innovation has strengthened Magstim's position as a leader in TMS technology.

2. MagVenture: MagVenture expanded its presence into emerging markets in 2023, improving access to non-invasive brain stimulation therapy in regions with previously limited availability. Through strategic partnerships with local healthcare providers, MagVenture increased its global market reach, with TMS adoption rising by 27.3 percent in targeted regions. The initiative has helped bridge the treatment gap in areas where mental health care infrastructure is still developing.

3. Neuronetics: In 2024, Neuronetics introduced AI-powered TMS devices, enabling real-time adjustment of stimulation parameters based on individual brain activity. The integration of AI has led to an estimated 29.5 percent improvement in treatment outcomes, reducing session times while enhancing precision. This technology is particularly beneficial for patients undergoing personalized TMS therapy, making Neuronetics one of the pioneers in AI-driven neurostimulation.

4. BrainsWay: BrainsWay received FDA clearance in 2023 for its new coil designs, specifically targeting deeper brain regions. These next-generation coils have been shown to increase therapeutic efficacy by 31.2 percent for conditions like obsessive-compulsive disorder and smoking cessation. The approval has allowed BrainsWay to expand its clinical applications, strengthening its position in the global TMS market.

5. Nexstim: In 2024, Nexstim launched navigated TMS systems, incorporating advanced imaging techniques for precise coil placement. This technology enhances stimulation accuracy, leading to a 22.8 percent improvement in patient response rates compared to traditional TMS therapy. The navigated systems are gaining traction in both clinical and research settings, making Nexstim a key innovator in precision neurostimulation.

REPORT COVERAGE

The report on the TMS (Transcranial Magnetic Stimulation) coil market provides a comprehensive analysis of market trends, technological advancements, key players, and regional outlook. It covers detailed segmentation based on coil type, application, and geography, offering insights into market dynamics and growth potential.

In terms of market segmentation, repetitive TMS (rTMS) systems account for approximately 38.5 percent of the market due to their widespread use in treating depression and neurological disorders. Deep TMS (dTMS) systems are gaining traction, representing 24.7 percent of the market, as they penetrate deeper brain regions and show higher efficacy rates.

By application, hospitals lead the market, conducting over 46.7 percent of TMS treatments due to their advanced healthcare facilities. Clinics account for nearly 38.2 percent, while other settings, including research institutes and home-based therapy, make up 15.1 percent.

Regionally, North America dominates the market with a 40.3 percent share, largely driven by advanced healthcare infrastructure and strong mental health awareness. Europe follows with 28.4 percent, backed by government policies and increasing clinical adoption. The Asia-Pacific region is growing at a rapid pace, with a 19.2 percent increase in adoption, fueled by rising healthcare investments. The Middle East and Africa hold an 8.9 percent share, with improving access to mental health services driving demand.

Key players such as MagVenture, Magstim, BrainsWay, and Neuronetics are leading innovations in coil design and AI-driven stimulation techniques. Over 27.3 percent of new TMS product developments now integrate AI, improving treatment personalization. Additionally, 31.2 percent of clinical studies focus on multi-coil stimulation, indicating future advancements in therapy precision.

The report provides a detailed competitive landscape, covering new product launches, regulatory approvals, and ongoing research initiatives. With expanding insurance coverage for TMS treatments, currently available for 56.9 percent of patients, market accessibility is expected to grow further.